Higher cardiovascular risk and impaired benefit of antihypertensive treatment in hypertensive patients requiring additional drugs on top of randomized therapy: Is adding drugs always beneficial?

Journal of Hypertension

Volumn 30, Issue 11, 2012, Pages 2202-2212

  Zhang, Yuqing ^a,b   Zhang, Xuezhong ^a,b   Liu, Lisheng ^a,b   Wang, Yang ^a   Tang, Xinran ^a   Zanchetti, Alberto ^c  

^a FUWAI HOSPITAL   (China)

^b Beijing Hypertension League Institute   (China)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

antihypertensive therapy; cardiovascular disease; resistant hypertension; therapeutic strategies; trials

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIURETIC AGENT; FELODIPINE; HYDROCHLOROTHIAZIDE; PLACEBO;

ADD ON THERAPY; ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 84867748328     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283582eec     Document Type: Article

References (25)

1. Zanchetti A. Evidence-based medicine in hypertension: what type of evidence? J Hypertens 2005; 23:1113-1120.
2. World Health Organization-International Society of Hypertension Writing Group. World Health Organization-International Society of Hypertension statement on management of hypertension. J Hypertens 2003; 21:1983-1992.
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al., National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertens 2003; 42:1206-1252.
4. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
5. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, et al. Japanese Society of Hypertension Committee. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32:3-107.
6. Sanchez RA, Ayala M, Baglivo H, Velazquez C, Burlando G, Kohlmann O, et al., Latin America Expert Group. Latin American Guidelines on Hypertension. Latin American Expert Group. J Hypertens 2009; 27:905-922.
7. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 2009; 27:923-934.
8. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caul-field M, et al. Reappraisal of European Guidelines on Hypertension Management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27:2121-2158.
9. Liu L, Zhang Y, Liu G, Zhang X, Zanchetti A. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005; 23:2157-2172.
10. Zhang Y, Zhang X, Liu L, Zanchetti A. Is a SBP target below 140mm Hg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. Eur Heart J 2011; 32:1500-1508.
11. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the casual effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11:561-570.
12. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive- drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 2010; 375: 906-915.
13. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895-905.
14. Zanchetti A. Hypertension: meta-analyses-first-rank evidence or second-hand information? Nat Rev Cardiol 2011; 8:249-251.
15. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366:1545-1553.
16. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90:1786-1793.
17. Zanchetti A. Hypertension: cardiac hypertrophy as a target of anti-hypertensive therapy. Nat Rev Cardiol 2010; 7:66-67.
18. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
19. TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular event in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372:1174-1183.
20. Zanchetti A. Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced? J Hypertens 2009; 27:1509-1520.
21. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al., SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21:875-886.
22. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al., SCOPE Study Group. The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. J Hypertens 2004; 22:1605-1612.
23. Weber MA, Julius S, Kjeldsen SE, Jia Y, Brunner HR, Zappe DH, et al. Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy. J Hypertens 2012; 30:2213-2222.
24. Staessen J, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension in Europe. Lancet 1997; 350:757-764.
25. Thijs L, Richart T, de Leeuw PW, Kuznetsova T, Grodzicki T, Kawecka-Jaszcz K, et al. Morbidity and mortality on combination versus mono-therapy: a posthoc analysis of the Systolic Hypertension in Europe trial. J Hypertens 2010; 28:865-874.